Kornimate/medical-research-clean huggingface dataset:
a prospective study comparing vivaer to alternative surgical procedures to treat nasal airway obstruction in patients with nasal valve dysfunction.

Conditions: Nasal Airway Obstruction

Summary: the purpose of this study is to compare the clinical outcomes of the vivaer procedure to functional rhinoplasty and septoplasty surgery for the treatment of nasal airway obstruction (nao) to establish non-inferiority.

the purpose of this study is to compare the clinical outcomes of the vivaer procedure to functional rhinoplasty and septoplasty surgery for the treatment of nasal airway obstruction (nao) to establish non-inferiority by using the nose scale to evaluate the significance of a patient's nasal obstruction both before and after the procedure for the primary endpoint.

Eligibility criteria:
inclusion criteria: * age 22 to 85 years old (inclusively). * willing and able to provide consent. * willing and able to comply with the patient-specific requirements outlined in the study protocol. * has access to a mobile device, tablet, or computer with internet access and has access to an email address. * seeking treatment for nao * has a nose score of ≥55 indicating severe to extreme nao. * have a positive modified cottle maneuver. * planning either to undergo an intervention for nao that includes one of the following as the primary approach. * vivaer procedure for repair of nasal valve dysfunction (may include inferior turbinate and septal swell body as additional treated areas) * functional rhinoplasty surgery addressing the nasal valve and/or lateral nasal wall (may be combined with septoplasty and/or turbinoplasty performed alone or in combination). * septoplasty alone or in combination with turbinate reduction. exclusion criteria: * has had nasal surgery (including sinus surgery) within the last 3 months. * has had a previous rhinoplasty (functional or cosmetic), septoplasty, inferior turbinate reduction, or vivaer procedure to address nao symptoms. * has extreme nasal pathology, a history of extreme nasal injuries, or an abnormal nasal condition (e.g. septal perforation or empty nose syndrome) that may be exacerbated by surgery. * has a medical condition(s) that may impair normal healing processes or be exacerbated by the stress of surgery. * has chronic rhinitis that is refractory to medications or rhinitis medicamentosa. * has poorly controlled chronic rhinosinusitis disease. * rhinoplasty is being performed primarily for cosmesis. * is receiving, planning to receive, or has received a latera absorbable nasal implant at any time. * planning to have sinus or cosmetic surgery (e.g., functional endoscopic sinus surgery, cosmetic rhinoplasty) or a surgery involving the airway (e.g., hypoglossal nerve stimulation surgery, uvuloplasty, tonsillectomy, tongue base or soft palate interventions) within 6 months following enrollment.

Keywords: nao nasal airway obstruction nasal nasal airway compaer vivaer nasal valve dysfunction nose
lactoferrin + vitamin e + zinc for hormonal acne

Conditions: Hormonal Acne

Summary: we previously showed that twice daily intake of a combination of 100 mg lactoferrin, 11 iu vitamin e, and 5 mg zinc significantly reduced both inflammatory and non-inflammatory acne lesions compared to placebo control. in that study, females showed an overall better response compared to males in terms of total lesions. we speculated that the gender effect may be due to mitigation of the pre- menstrual flare-ups women have that lead to recurring acne, making them have a better response. the objectives of this study are: 1.) to characterize the efficacy and safety of 100 mg lactoferrin + 11 iu vitamin e + 5 mg zinc in the adult female population who suffer from hormonal acne, 2.) to determine whether the anti-acne effect is maintained after treatment stops.


Eligibility criteria:
inclusion criteria: 1. females aged 22-50. 2. at least 3 inflammatory acne lesions, mostly found on (but not limited to) the lower face 3. not responsive to conventional treatment 4. clinical diagnosis of mild to moderate acne according to lehmann et. al. exclusion criteria: 1. females who are pregnant (confirmed by a pregnancy test), breast- feeding, or planning a pregnancy. 2. post-menopausal women 3. current or recent (within 3 months) use of any topical or oral anti- acne products, 4. hormonal contraceptive intake in the preceding six months 5. a cancer diagnosis within the past 5 years 6. history of hypersensitivity to any component of the test product. 7. current imuunosuppression. specifically, these include patients with co-morbidities such as diabetes, hiv, chronic diseases patients requiring maintenance medications, such as vascular disease, * hepatitis, eczema, psoriasis, or acute febrile/infectious illnesses * (i.e. dengue, pneumonia, etc)
severe male factor infertility management

Conditions: Oligoasthenoteratozoospermia

Summary: this study is the first to evaluate the effect of oral supplementation with antioxidants combined with lifestyle modification for severe male factor partner of couples undergoing icsi.

patients underwent a therapy of a three-month period of treatment with either oral l-carnitine only (2g daily) or oral carnitine (2g daily) combined with modifiable lifestyle factors.

Eligibility criteria:
inclusion criteria: * long protocol for ovulation * oligoasthenoteratozoospermic male partner ( (count \ 99%). * fresh semen samples. exclusion criteria: * day 3 embryo transfer * incomplete icsi cycles * endometrial thickness\> 7mm

Keywords: oligoasthenoteratozoospermia male factor managment intacytoplasmic sperm injection
treatment of chronic hepatitis with sofosbuvir in combination with ribavirin with or without pegylated interferon: north india gastroenterology consortium

Conditions: Hepatitis, Chronic

Summary: of the six main genotypes of the hepatitis c virus (hcv), genotypes 2 and 3 account for approximately 30% of chronic infections worldwide. in north india, genotypes 3 and 1 account for 95% of chronic hepatitis c patients the first three direct-acting antiviral agents to receive fda approval-boceprevir, telaprevir, and simeprevir-do not currently have a role in the treatment of genotype 3 infection. in contrast, the direct-acting antiviral agents, daclatasvir and sofosbuvir, have good activity against all genotypes. the svr rates of 90 - 100% in genotype 3 were achieved with oral sofosbuvir plus ribavirin regimen to 24 weeks. similar svr rates were achieved in genotype 1 with oral sofosbuvir plus weight based ribavirin and pegylated interferon alpha 2 a. however, the ongoing discovery and development of agents that directly target various stages of hcv replication are likely to provide hcv-infected patients with effective interferon-free therapy. hcv genotype 3 infection is associated with a higher incidence of hepatic steatosis, more rapid progression of fibrosis, and possibly a greater risk of hepatocellular carcinoma than is hcv genotype 2 infection.moreover, patients with hcv genotype 3 infection are less responsive to peginterferon based treatment than are patients with hcv genotype 2 infection.

sofosbuvir is an oral nucleotide analogue inhibitor of the hcv ns5b polymerase that is effective against hcv genotypes 2 and 3 when it is administered in combination with weight based ribavirin for 24 weeks. in genotype 1, a combination of pegylated interferon alpha 2 a with oral sofosbuvir and weight based ribavirin for 12 weeks resulted in 90 -100 % sustained virological response rates (svr). these svr rates for chronic hepatitis c genotypes 1,2 and 3 are all based on western studies. the investigators plan to conduct a retrospective study in northern india region on patients treated with sofosbuvir and ribavirin or sofosbuvir, ribavirin and peginterferon alpha 2a. the purpose of the investigators study is to assess the percentage of patients with sustained virologic response.

Eligibility criteria:
inclusion criteria: * age more then 18 years. * patient who on treatment of either sofosbuvir and ribavirin (24 weeks) or sofosbuvir, ribavirin and peginterferon (12 weeks). exclusion criteria: * patient who are lost to follow up.
efficacy of tranexamic acid on blood loss during percutaneous nephrolithotomy.

Conditions: Renal Stones; Nephrolithiasis

Summary: efficacy of tranexamic acid on blood loss during percutaneous nephrolithotomy. a double-blind, placebo-controlled randomized clinical trial.

to evaluate whether intravenous tranexamic acid or tranexamic acid in the irrigation fluid in percutaneous nephrolithotomy (pcnl) in reducing bleeding during and after pcnl.

Eligibility criteria:
inclusion criteria: * patient 18 years or older * stones ≥ 2 cm and/or mild to moderate hydronephrosis. exclusion criteria: * age \<18 years or pregnancy * bilateral simultaneous pcnl * morbid obesity (bmi \>40) * refuse to complete study requirements * untreated uti * atypical bowel interposition by ct * tumour in the presumptive access tract area or potential malignant kidney tumour

Keywords: tranexamic acid percutanous nephrolithotomy
microwave ablation of resectable liver tumors

Conditions: Hepatocellular Carcinoma; Liver Cancer

Summary: the purpose of this protocol is to pathologically evaluate the destruction by microwave ablation of primary and metastatic liver tumors. the primary aim is to measure tissue destruction with the medwaves microwave ablation/ coagulation ablation system.

minimally invasive surgical alternatives are becoming more attractive for the treatment of malignancy.the goal is to reduce morbidity and mortality and increase the ability to treat patients in the outpatient setting. image-guided ablation is becoming an attractive alternative because of its relative low cost, its ability to provide large regions of coagulative necrosis in a controlled fashion, and its relatively low toxicity. although image-guided ablative techniques have been extensively investigated for the treatment of liver tumors, there has been limited experience with microwave ablation (mwa) in the liver. this study will evaluate the treatment effect of mwa in liver tumors. patients undergoing planned surgical removal of liver tumors will have the tumors intra-operatively treated with mwa. the histological changes will be evaluated upon removal of the specimen.

Eligibility criteria:
inclusion criteria: * diagnosis of primary or metastatic liver cancer for which surgery is planned * all participants need to be fully able to give informed consent exclusion criteria: * mental or legal incompetence * impaired decision-making capacity * pregnant women may not participate

Keywords: liver cancer tumors
impact of early pcsk9 inhibitor on heart after acute myocardium infarction

Conditions: Early PCSK9 Inhibitor on Ventricular Remodling

Summary: this is a prospect, multi-center, random study to investigate whether early offering pcsk9 inhibitor to acute myocardium infarction(ami) can alleviate ventricular remodeling after primary percutaneous intervention(ppci). totally,twenty acute myocardium infarction subjects will be enrolled in this study after consent information. after randomization, the control group will receive standard therapy for ami including ppci. the experiment group will receive first pcsk9 inhibitor before ppci, then twice a month until 3 months later. six month after ami, myocardial salvage index will be used to evaluate ventricular remodeling. tni peaking time and ldl control rates also will be recorded and compared.


Eligibility criteria:
inclusion criteria: 1. subject must be at least 18 years of age and less than 80 years old 2. patients should have undergone successful percutaneous coronary intervention with drug-eluting stent for ami and lad should be the only culprit vessel. 3. subject understand the study requirements and the treatment procedures and provided informed consent before the procedure exclusion criteria: 1. female of childbearing potential, unless a recent pregnancy test is negative, who possibly plan to become pregnant any time after enrollment into this study 2. known hypersensitivity or contraindication to study medications 3. plan to receive revascularization in next six month. 4. have received revascularization before. 5. subjects with life expectation less than one year. 6. subjects with active malignant tumor 7. subjects with severe liver or renal dysfunction（alt \>5倍ula，egfr\<15ml/min/1.73mm2） 8. other conditions which the investigators think not applicable to the study.
observational non-interventional study with enbrel (etanercept) in patients with ankylosing spondylitis

Conditions: Spondylitis, Ankylosing

Summary: this observational study will be a documentation of the prescribing and administration practices of enbrel® and their impact on ankylosing spondylitis patients outcome in a real life setting.

the study population will be described using standard descriptive statistics for demographic, clinical, medical, characteristics, as well as for standard health-related quality of life and functional disability questionnaires .

Eligibility criteria:
inclusion criteria: * proven diagnosis of ankylosing spondylitisin accordance with local guidelines * patients treated as an outpatient exclusion criteria: * patients who suffer from hypersensitivity to the active substance etanercept or to any of the excipients of enbrel®. * treatment with enbrel® should not be initiated in patients with active infections including chronic or localised infections. * patients with sepsis or risk of sepsis should not be treated.

Keywords: ankylosing spondylitis
maintenance programme after weight loss

Conditions: Weight Loss; Morbid Obesity

Summary: the aim of this study is to compare a weight reduction programme with and without a maintenance programme in patients with severe obesity.


Eligibility criteria:
inclusion criteria: * bmi 35 kg/m2 or more * age 18-65 years exclusion criteria: * type 1 diabetes * major alcohol problem * acute psychic disease, eating behavior, pregnancy, severe disease (cancer, unstable coronary disease, severe liver or kidney disease), or the patient has been in this treatment within the past 5 years

Keywords: maintenance therapy
reduced er-qol in families after congenital cataract surgery

Conditions: Prospective Cross-sectional Study

Summary: children after congenital cataract surgery experience a lower quality of life and reduced functional vision. their families have also been seriously affected. investigators should pay more attention to them, and measures should be administered to families.


Eligibility criteria:
inclusion criteria: * visually not significant cataract, and ophthalmic surgery (incisional or laser) within one month exclusion criteria: * parents who were inability to communicate were also excluded
placebo controlled study of baclofen for gerd in children with cerebral palsy

Conditions: Cerebral Palsy; GERD

Summary: despite the use of proton pump inhibitors and available prokinetics, medical therapy is ineffective in an important number of children with cerbreal palsy (cp) and gastroesophageal reflux disease (gerd), and failure of medical therapy is associated with a substantial morbidity. many patients, particularly children with cp and gerd, continue to experience complications despite aggressive therapy because antisecretory medications do not address the primary reflux mechanism (tlesr). furthermore, in patients with cp, surgical options are fraught with serious complications and long-term morbidity. because the available treatment options for children with cp and intractable gerd are limited, new therapies are urgently needed. baclofen, which has been shown in animals and humans to decrease tlesrs, may be a good alternative for the treatment of children with cp with intractable gerd.

despite the use of proton pump inhibitors and available prokinetics, medical therapy is ineffective in an important number of children with cerbreal palsy (cp) and gastroesophageal reflux disease (gerd), and failure of medical therapy is associated with a substantial morbidity. many patients, particularly children with cp and gerd, continue to experience complications despite aggressive therapy because antisecretory medications do not address the primary reflux mechanism (tlesr). this is a placebo controlled trial of baclofen for the treatment of gerd in children with cp.

Eligibility criteria:
inclusion criteria: * 3-18 years old * diagnosis of cerebral palsy * symptoms of gerd for at least 3 months * at least 8 weeks on bid therapy with a ppi at a therapeutic dose at time of enrollment * normal upper gastrointestinal barium contrast study (ugi) * have a g-tube that is used for more than 75% of calories and a stable feeding schedule for at least 2 weeks * if seizures are present, they need to be controlled and on stable medications for 4 weeks exclusion criteria: * underlying electrolyte disturbance * history of nissen fundoplication * renal insufficiency * currently receiving baclofen * baclofen allergy * uncontrolled seizure disorder * lack of informed consent

Keywords: gerd
ultrasound-guided block of the lateral femoral cutaneous nerve in pediatric patients

Conditions: Burns

Summary: the purpose of this study is to determine whether either a peripheral nerve block under ultrasound (u/s) guidance of the lateral femoral cutaneous nerve (lfcn), versus an u/s guided block of the nerve followed by continuous catheter infusion of local anesthetic, offers better post-operative analgesia in pediatric burn patients undergoing reconstructive surgery, than the current analgesic regimen of subcutaneous local anesthetic infiltration. eligible subject, pediatric patients having reconstructive surgery for burns, having skin graft donor sites of the lateral thighs, will be randomized into three groups: control (having local infiltration of site), ultrasound guided nerve block, or ultrasound guided nerve block with catheter placement --fascia iliac. post-operative comfort will be assessed over the next 48 hours.


Eligibility criteria:
inclusion criteria: * going for reconstructive surgery requiring split thickness skin graft * patient's donor site will be in distribution of lateral femoral cutaneous nerve * age \>=2 and \<22 * patient emotionally/intellectually able to describe intensity of post-op pain using vas or wong- baker faces scale. exclusion criteria: * potential block/catheter site infected or burned. * intolerance/allergy to local anesthetics * bmi \> 30 * american society of anesthesiologists (asa) score \> 2

Keywords: burn skin graft donor site analgesia for donor site
double-blind, four week trial of [s,s]-reboxetine and atomoxetine in adults with attention deficit hyperactivity disorder.

Conditions: Attention Deficit Hyperactivity Disorder

Summary: this study will compare the safety and efficacy of \[s,s\]-reboxetine to atomoxetine in the treatment of adult patients with attention deficity-hyperactivity disorder.


Eligibility criteria:
inclusion criteria: 1. diagnosis of attention deficit hyperactivity disorder according to dsm-iv criteria. 2. score of 24 or higher on the adult adhd investigator symptom rating scale 3. score of 4 or higher on the clinician global impression - severity scale exclusion criteria: 1. significant comorbid psychiatric diagnoses 2. significant risk of suicidal or violent behavior
low intensity extracorporeal shock wave therapy (li-eswt) for erectile dysfunction

Conditions: Erectile Dysfunction

Summary: low-intensity extracorporeal shock wave therapy (li-eswt) has shown promise as a novel treatment for erectile dysfunction (ed), though the the mechanism of action and optimal protocol for administration has not been well-established. the aim of this study is to assess for subjective and objective improvements in erectile function following treatment with li-eswt.

eligible patients will be enrolled as outlined below. prior to initiation of li-eswt treatments, patients will complete validated questionnaires to assess erectile function. in addition, patients will undergo induction of artificial erection in clinic with assessment of penile blood flow using penile doppler. intracavernosal pressure measurements will be obtained. a corporal aspirate will be drawn and examined for levels of neuronal nitric oxide synthase, endothelial nitric oxide synthase, brain-derived neurotropic factor and vascular endothelial growth factor. patients will then receive twice-weekly li-eswt treatments of 0.2mj/mm\^2 over 3 treatment sites along the dorsal penile shaft, 1500 shocks per treatment (500 shocks per treatment site), for a total of 3000 shocks per week, for 6 weeks of treatment (totally 18,000 shocks). following li-eswt treatments, patients will complete the same validated questionnaires, penile doppler studies, corporal aspirates and measurement of intracavernosal pressures immediately following the final li-eswt treatment, 4-6 weeks following completion of treatment, and again at 3 and 6 months following completion of treatment.

Eligibility criteria:
inclusion criteria: * male veterans between 40 and 80 years of age * known or suspected vasculogenic erectile dysfunction based on clinical history * in an active sexual relationship with a minimum of 2 sexual attempts per month for at least one month prior to enrollment * suffering from ed for at least 6 months * international index of erectile function - ef domain score between 17-25, erection hardness score score ≥ 1 * testosterone level between 300-1000ng/dl within one month prior to enrollment * hgb a1c ≤ 8% within one month prior to enrollment * able to consent to study participation exclusion criteria: * erectile dysfunction due to radical prostatectomy, prior pelvic surgery, or radiation therapy to the pelvis within 12 months prior to enrollment. * men with known neurogenic or psychogenic ed * anatomic malformations of the penis including peyronie's disease * testosterone \ 1000ng/dl * hgb a1c \> 8% * international normalized ratio \> 2.5, and men on any blood thinners other than 81mg aspirin participants will be required to discontinue all erectogenic medications for 1 months prior to initiation of treatment and will not be permitted to use erectogenic medications for the duration of the treatment study.

Keywords: erectile dysfunction low intensity shock wave therapy